


**IN THE CLAIMS:**

(Currently Amended): METHODS ~~AND COMPOSITIONS~~ FOR TREATING AGE-RELATED BEHAVIORAL DISORDERS IN COMPANION ANIMALS

## IN THE CLAIMS:


1. (Currently Amended): A method of treating an age-related behavioral disorder in a companion animal comprising administering to a companion animal in need of such treatment a therapeutically effective amount of a compound of Formula I,

### FORMULA I



wherein R<sup>1</sup> and R<sup>2</sup> are each independently selected from the group consisting of hydrogen; (C<sub>1</sub>-C<sub>6</sub>) alkoxy; benzyloxy; phenoxy; hydroxy; phenyl; benzyl; halo; nitro; cyano; -COR<sup>5</sup>; -COOR<sup>5</sup>; -CONHR<sup>5</sup>; -NR<sup>5</sup>R<sup>6</sup>; -NR<sup>5</sup>COR<sup>6</sup>; -OCONR<sup>5</sup>R<sup>6</sup>; -NHCOOR<sup>5</sup>; (C<sub>1</sub>-C<sub>6</sub>) alkyl which may be substituted with from 1 to 3 fluorine atoms; SO<sub>p</sub>CH<sub>2</sub>-phenyl or SO<sub>p</sub>(C<sub>1</sub>-C<sub>6</sub>) alkyl, wherein p is 0, 1 or 2; pyridylmethoxy or thienylmethoxy; 2-oxazolyl; 2-thiazolyl; and benzenesulfonamide; wherein the phenyl moieties of said phenoxy, benzyloxy, phenyl, benzyl and benzenesulfonamide groups, the pyridyl and thienyl moieties of said pyridylmethoxy or thienylmethoxy groups, and the oxazolyl and thiazolyl moieties of said 2-oxazolyl and 2-thiazolyl groups may be substituted with 1 or 2 substituents independently selected from the group consisting of halo, (C<sub>1</sub>-C<sub>4</sub>) alkyl, trifluoromethyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, cyano, nitro and hydroxy;

or R<sup>1</sup> and R<sup>2</sup> are attached to adjacent carbon atoms and form, together with the carbon atoms to which they are attached, a group of Formula 2:



**FORMULA 2**

wherein  $R^3$  is hydrogen or  $(C_1-C_6)$  alkyl; J is oxygen, sulfur or  $NR^4$ ;  $R^4$  is hydrogen or  $(C_1-C_4)$  alkyl; and Q is oxygen, sulfur, NH,  $CHCH_3$ ,  $C(CH_3)_2$ ,  $-CH=CH-$ , or  $(CH_2)_I$  wherein I is an integer from 1 to 3;

X is oxygen or sulfur;

Y is  $-(CH_2)_m-$ ,  $-CH=CH(CH_2)_n-$ , or  $-O(CH_2)_m-$ , wherein n is an integer from 0 to 3, and m is an integer from 1 to 3;

$R^5$  and  $R^6$  are each independently selected from the group consisting of hydrogen,  $(C_1-C_6)$  alkyl, phenyl, and benzyl, wherein the phenyl moieties of said phenyl and benzyl groups may be substituted with 1 or 2 substituents independently selected from the group consisting of fluoro, chloro, bromo, iodo,  $(C_1-C_4)$  alkyl, trifluoromethyl,  $(C_1-C_4)$  alkoxy, cyano, nitro and hydroxy; or  $NR^5R^6$  together form a 4 or 5 membered ring wherein one atom of the ring is nitrogen and the other is ~~are~~ carbon, oxygen or nitrogen; or  $NR^5COR^6$  together form a 4- or 5-membered lactam ring;

L is phenyl, phenyl- $(C_1-C_6)$  alkyl, cinnamyl or pyridylmethyl, wherein the phenyl moieties of said phenyl and phenyl- $(C_1-C_6)$  alkyl may be substituted with 1 to 3 substituents independently selected from the group consisting of  $(C_1-C_6)$  alkyl,  $(C_1-C_6)$  alkoxy,  $(C_1-C_4)$  alkoxycarbonyl,  $(C_1-C_6)$  alkylcarbonyl,  $-OCONR^5R^6$ ,  $-NHCOOR^5$ , and halo; or L is a group of Formula 3:



5. (Previously Amended): A method of treating disorientation or confusion in a companion animal comprising administering to a companion animal in need of such treatment a therapeutically effective amount of a compound of Formula I.

6. (Previously Amended): A method of improving the social interactions of a companion animal comprising administering to a companion animal in need of such improvement a therapeutically effective amount of a compound of Formula I.

*D'cont*  
7. (Previously Amended): A method of adjusting the sleep-wake cycle of a companion animal comprising administering to a companion animal in need of such adjustment a therapeutically effective amount of a compound of Formula I.

8. (Previously Amended): A method of treating inappropriate elimination in a companion animal comprising administering to a companion animal in need of such treatment a therapeutically effective amount of a compound of Formula I.

9. (Currently Amended): The method of claim 1 or 3-8 wherein the companion animal is a cat or a dog.

10. (Cancelled).

11. (Previously Amended): The method of Claim 1 wherein the compound of Formula 1 is selected from the group consisting of:

5,7-dihydro-7-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-7-ethyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-chloro-5-thiophenemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-methyl-4-thiazolemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(3-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(4-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

6,8-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-7H-pyrrolo[5,4-g]-1,2-benzisoxazol-7-one; and

5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

12. (Previously Amended): The method of claim 11 wherein the compound of Formula 1 is 5,7-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-

6-one.

13. – 16 (Cancelled).

17. (Previously Amended): A dosage form of a compound of Claim 1 for use in the treatment of an age-related behavioral disorder in a companion animal.

18. (Original): The dosage form of claim 17 wherein said dosage form is a tablet, troche, dispersion, suspension, solution, capsule, or patch.

*D'cont*  
19. (Previously Amended): The dosage form of Claim 18 wherein the compound of Claim 1 is selected from the group consisting of:

5,7-dihydro-7-methyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-7-ethyl-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-chloro-5-thiophenemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[2-[1-(2-methyl-4-thiazolemethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(3-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

3-[2-[1-(4-bromophenylmethyl)-4-piperidinyl]ethyl]-5,7-dihydro-6H-

pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

5,7-dihydro-3-[3-[1-(phenylmethyl)-4-piperidinyl]propyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one;

6,8-dihydro-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-7H-pyrrolo[5,4-g]-1,2-benzisoxazol-7-one; and

5,7-dihydro-3-[2-(1-(phenylmethyl)-4-piperidinyl)ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

20. (Currently Amended): The dosage form of claim 19 wherein the compound of Formula 1 is 5,7-dihydro-3-[2-1-[(phenylmethyl)-4-piperidinyl]ethyl]-6H-pyrrolo[4,5-f]-1,2-benzisoxazol-6-one.

21. (Previously Amended): The dosage form of claim 20 wherein said dosage form comprises from about 0.001 mg to about 100 mg of the compound of Claim 1.